CAMBRIDGE, Mass., Dec. 15 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ - News) today announced that Synvisc® (hylan G-F 20), a market- leading viscosupplement used to treat pain due to osteoarthritis of the knee, will maintain a separate reimbursement code and rate for 2007. The Centers for Medicare and Medicaid Services (CMS) reversed a decision made earlier this fall that would have placed all viscosupplement products in the same reimbursement code for billing next year. As a result of the CMS decision, effective January 1, 2007, the Medicare payment rate will continue to be 106 percent of Synvisc's Average Selling Price (ASP) calculated from data submitted to CMS.
